This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Drake, W. M. Articles by Shalet, S. M. Search for Related Content PubMed PubMed Citation Articles by Drake, W. M. Articles by Shalet, S. M.

Optimizing GH Therapy in Adults and Children

Departments of Endocrinology, St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom; and Christie Hospital, Manchester, United Kingdom

Correspondence: Address all correspondence and requests for reprints to: Dr. W. M. Drake, Department of Endocrinology, St. Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, United Kingdom. E-mail: w.m.drake{at}mds.qmw.ac.uk

Until the advent of modern neuroradiological imaging techniques in 1989, a diagnosis of GH deficiency in adults carried little significance other than as a marker of hypothalamo-pituitary disease. The relatively recent recognition of a characteristic clinical syndrome associated with failure of spontaneous GH secretion and the potential reversal of many of its features with recombinant human GH has prompted a closer examination of the physiological role of GH after linear growth is complete. The safe clinical practice of GH replacement demands a method of judging overall GH status, but there is no biological marker in adults that is the equivalent of linear growth in a child by which to judge the efficacy of GH replacement. Assessment of optimal GH replacement is made difficult by the apparent diverse actions of GH in health, concern about the avoidance of iatrogenic acromegaly, and the growing realization that an individual’s risk of developing certain cancers may, at least in part, be influenced by cumulative exposure to the chief mediator of GH action, IGF-I. As in all areas of clinical practice, strategies and protocols vary between centers, but most physicians experienced in the management of pituitary disease agree that GH is most appropriately begun at low doses, building up slowly to the final maintenance dose. This, in turn, is best determined by a combination of clinical response and measurement of serum IGF-I, avoiding supraphysiological levels of this GH-dependent peptide. Numerous studies have helped define the optimum management of GH replacement during childhood. The recent requirement to measure and monitor GH status in adult life has called into question the appropriateness of simplistic weight- and surface area-based dosing regimens for the management of GH deficiency in childhood, with reliance on linear growth as the sole marker of GH action. It is clear that the monitoring of parameters other than linear growth to help refine GH therapy should now be incorporated into childhood GH treatment protocols. Further research will be required to define the optimal management of the transition from pediatric to adult GH replacement; this transition will only be possible once the benefits of GH in mature adults are defined and accepted by pediatric and adult endocrinologists alike.

This article has been cited by other articles:

				L.-L. Norrman, G. Johannsson, K. S. Sunnerhagen, and J. Svensson Baseline Characteristics and the Effects of Two Years of Growth Hormone (GH) Replacement Therapy in Adults with GH Deficiency Previously Treated for Acromegaly J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2531 - 2538. [Abstract] [Full Text] [PDF]

				N. di Iorgi, A. Secco, F. Napoli, C. Tinelli, A. Calcagno, N. Fratangeli, L. Ambrosini, A. Rossi, R. Lorini, and M. Maghnie Deterioration of Growth Hormone (GH) Response and Anterior Pituitary Function in Young Adults with Childhood-Onset GH Deficiency and Ectopic Posterior Pituitary: A Two-Year Prospective Follow-Up Study J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3875 - 3884. [Abstract] [Full Text] [PDF]

				G. Gotherstrom, B.-A. Bengtsson, I. Bosaeus, G. Johannsson, and J. Svensson A 10-Year, Prospective Study of the Metabolic Effects of Growth Hormone Replacement in Adults J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1442 - 1445. [Abstract] [Full Text] [PDF]

				C. Franco, G. Johannsson, B.-A. Bengtsson, and J. Svensson Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4408 - 4414. [Abstract] [Full Text] [PDF]

				D Maiter, R Abs, G Johannsson, M Scanlon, P J Jonsson, P Wilton, and M Koltowska-Haggstrom Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur. J. Endocrinol., August 1, 2006; 155(2): 253 - 260. [Abstract] [Full Text] [PDF]

				J. Svensson, G. Johannsson, A. Iranmanesh, K. Albertsson-Wikland, J. D Veldhuis, and B.-A. Bengtsson GH secretory pattern in young adults who discontinued GH treatment for GH deficiency and decreased longitudinal growth in childhood. Eur. J. Endocrinol., July 1, 2006; 155(1): 91 - 99. [Abstract] [Full Text] [PDF]

				B. Saller, A. F Mattsson, P. H Kann, H. P Koppeschaar, J. Svensson, M. Pompen, and M. Koltowska-Haggstrom Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults - comparison between Sweden, The Netherlands and Germany. Eur. J. Endocrinol., June 1, 2006; 154(6): 843 - 850. [Abstract] [Full Text] [PDF]

				S Pekic, M Doknic, D Miljic, M Joksimovic, J Glodic, M Djurovic, C Dieguez, F Casanueva, and V Popovic Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly. Eur. J. Endocrinol., May 1, 2006; 154(5): 659 - 666. [Abstract] [Full Text] [PDF]

				H. J. Schneider, B. Saller, J. Klotsche, W. Marz, W. Erwa, H.-U. Wittchen, and G. K. Stalla Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur. J. Endocrinol., May 1, 2006; 154(5): 699 - 706. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF]

				A. Mukherjee, J. E Adams, L. Smethurst, and S. M Shalet Interdependence of lean body mass and total body water, but not quality of life measures, during low dose GH replacement in GH-deficient adults Eur. J. Endocrinol., November 1, 2005; 153(5): 661 - 668. [Abstract] [Full Text] [PDF]

				J. Bjork, K. Link, and E. M. Erfurth The Utility of the Growth Hormone (GH) Releasing Hormone-Arginine Test for Diagnosing GH Deficiency in Adults with Childhood Acute Lymphoblastic Leukemia Treated with Cranial Irradiation J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6048 - 6054. [Abstract] [Full Text] [PDF]

				A. Vigano, S. Mora, P. Manzoni, L. Schneider, S. Beretta, M. Molinaro, B. di Natale, and P. Brambilla Effects of Recombinant Growth Hormone on Visceral Fat Accumulation: Pilot Study in Human Immunodeficiency Virus-Infected Adolescents J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4075 - 4080. [Abstract] [Full Text] [PDF]

				B. Dubrovsky Book Review: Hormones, Health and Behaviour. A Socio-ecological and Lifespan Perspective Transcultural Psychiatry, June 1, 2005; 42(2): 339 - 342. [PDF]

				P. Kendall-Taylor, P. J Jonsson, R. Abs, E. M. Erfurth, M. Koltowska-Haggstrom, D. A. Price, and J. Verhelst The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma Eur. J. Endocrinol., April 1, 2005; 152(4): 557 - 567. [Abstract] [Full Text] [PDF]

				M. Maghnie, G. Aimaretti, S. Bellone, G. Bona, J. Bellone, R. Baldelli, C. de Sanctis, L. Gargantini, R. Gastaldi, L. Ghizzoni, et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement Eur. J. Endocrinol., April 1, 2005; 152(4): 589 - 596. [Abstract] [Full Text] [PDF]

				R. Coutant, F. B. de Casson, S. Rouleau, O. Douay, E. Mathieu, F. Gatelais, N. Bouhours-Nouet, C. Voinot, M. Audran, and J. M. Limal Divergent Effect of Endogenous and Exogenous Sex Steroids on the Insulin-Like Growth Factor I Response to Growth Hormone in Short Normal Adolescents J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6185 - 6192. [Abstract] [Full Text] [PDF]

				J.-O. Jansson and J. Svensson Growth Hormone (GH) Replacement in Women in Relation to Their Endogenous GH Secretion J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3066 - 3066. [Full Text] [PDF]

				R. C. C. Ryther, A. S. Flynt, B. D. Harris, J. A. Phillips III, and J. G. Patton GH1 Splicing Is Regulated by Multiple Enhancers Whose Mutation Produces a Dominant-Negative GH Isoform That Can Be Degraded by Allele-Specific Small Interfering RNA (siRNA) Endocrinology, June 1, 2004; 145(6): 2988 - 2996. [Abstract] [Full Text] [PDF]

				A. Mukherjee, J. P. Monson, P. J. Jonsson, P. J. Trainer, and S. M. Shalet Seeking the Optimal Target Range for Insulin-Like Growth Factor I during the Treatment of Adult Growth Hormone Disorders J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5865 - 5870. [Abstract] [Full Text] [PDF]

				A. M. Boot Body Composition and Bone Mineral Density in Adolescents with Partial Growth Hormone Deficiency J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5099 - 5100. [Full Text] [PDF]

				W. M. Drake, P. V. Carroll, K. T. Maher, K. A. Metcalfe, C. Camacho-Hubner, N. J. Shaw, D. B. Dunger, T. D. Cheetham, M. O. Savage, and J. P. Monson The Effect of Cessation of Growth Hormone (GH) Therapy on Bone Mineral Accretion in GH-Deficient Adolescents at the Completion of Linear Growth J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1658 - 1663. [Abstract] [Full Text] [PDF]

				Y. Song, S. Kato, and J. C. Fleet Vitamin D Receptor (VDR) Knockout Mice Reveal VDR-Independent Regulation of Intestinal Calcium Absorption and ECaC2 and Calbindin D9k mRNA J. Nutr., February 1, 2003; 133(2): 374 - 380. [Abstract] [Full Text] [PDF]

				Why start an adult on growth hormone? DTB, October 1, 2002; 40(10): 75 - 78. [Abstract] [Full Text] [PDF]

				D. C. O'Sullivan, T. A. M. Szestak, and J. M. Pell Regulation of IGF-I mRNA by GH: putative functions for class 1 and 2 message Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E251 - E258. [Abstract] [Full Text] [PDF]

				M. E. Molitch Diagnosis of GH Deficiency in Adults--How Good Do the Criteria Need to Be? J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 473 - 476. [Full Text] [PDF]